Watching Twist Bioscience Corporation? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsMaterial AgreementItem 1.01 · 8-KLOW RiskPositive
Twist Bioscience Corporation
www.twistbioscience.comFiled: Aug 4, 2026South San FranciscoCIK: 0001581280Biotechnology
AI Executive Summary
AI-powered analysis of 8-K filing content
Twist Bioscience Corporation completed a public offering of 3,125,000 shares at $96.00 per share, raising $300 million to fund expansion and ongoing projects. The underwriters exercised their option to purchase an additional 468,750 shares, demonstrating strong investor demand.
Key Takeaways
Twist Bioscience raised $300 million through a public offering of common stock at $96.00 per share
The underwriting syndicate (Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities) exercised their 30-day option to purchase 468,750 additional shares on August 5, 2026
2 more takeaways
Filing Overview
Form Type8-K
Filing DateAug 4, 2026
Item1.01
CategoryMaterial Agreement
CIK0001581280
Accession #001-38720
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering
What This Means
The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.